Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 14 | 2024 | 11835 | 1.190 |
Why?
|
Ventricular Function, Left | 8 | 2024 | 3870 | 0.640 |
Why?
|
Masks | 1 | 2020 | 209 | 0.600 |
Why?
|
Stroke Volume | 12 | 2024 | 5513 | 0.560 |
Why?
|
Eligibility Determination | 1 | 2020 | 419 | 0.540 |
Why?
|
Prosthesis Implantation | 1 | 2020 | 593 | 0.510 |
Why?
|
Heart-Assist Devices | 3 | 2021 | 1290 | 0.510 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3381 | 0.490 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 558 | 0.480 |
Why?
|
Cardiology | 2 | 2021 | 1723 | 0.430 |
Why?
|
Selenium | 1 | 2016 | 416 | 0.430 |
Why?
|
Infection Control | 1 | 2020 | 983 | 0.430 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2020 | 1387 | 0.370 |
Why?
|
Cardiomyopathies | 1 | 2022 | 1945 | 0.360 |
Why?
|
Myocytes, Cardiac | 2 | 2016 | 1656 | 0.350 |
Why?
|
Medicaid | 2 | 2020 | 2811 | 0.330 |
Why?
|
Angiotensin Receptor Antagonists | 2 | 2024 | 1025 | 0.300 |
Why?
|
Predictive Value of Tests | 1 | 2024 | 15273 | 0.300 |
Why?
|
Health Personnel | 1 | 2020 | 3310 | 0.270 |
Why?
|
Prosthesis-Related Infections | 2 | 2021 | 486 | 0.260 |
Why?
|
Fibroblasts | 1 | 2016 | 4091 | 0.250 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3086 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3206 | 0.250 |
Why?
|
Heart Transplantation | 1 | 2018 | 3217 | 0.230 |
Why?
|
Sex Characteristics | 3 | 2023 | 2627 | 0.230 |
Why?
|
Pandemics | 3 | 2021 | 8621 | 0.230 |
Why?
|
Telemedicine | 1 | 2021 | 3005 | 0.230 |
Why?
|
Myocardial Infarction | 2 | 2023 | 11891 | 0.230 |
Why?
|
Ramipril | 1 | 2023 | 97 | 0.210 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 159 | 0.210 |
Why?
|
Vascular Resistance | 1 | 2024 | 932 | 0.180 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 558 | 0.180 |
Why?
|
MicroRNAs | 1 | 2016 | 3784 | 0.170 |
Why?
|
Biphenyl Compounds | 1 | 2024 | 988 | 0.170 |
Why?
|
Glomerular Filtration Rate | 2 | 2024 | 2178 | 0.160 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2022 | 12281 | 0.150 |
Why?
|
Drug Combinations | 1 | 2024 | 2024 | 0.150 |
Why?
|
Coronary Circulation | 1 | 2024 | 1578 | 0.150 |
Why?
|
Cardiovascular Diseases | 2 | 2020 | 15740 | 0.150 |
Why?
|
Echocardiography | 3 | 2024 | 4980 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.150 |
Why?
|
Sodium | 1 | 2022 | 1601 | 0.140 |
Why?
|
Eicosapentaenoic Acid | 1 | 2020 | 613 | 0.130 |
Why?
|
Benzhydryl Compounds | 1 | 2022 | 942 | 0.130 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2024 | 1300 | 0.120 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2016 | 223 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.120 |
Why?
|
Humans | 23 | 2024 | 760261 | 0.120 |
Why?
|
Pre-Eclampsia | 1 | 2024 | 1230 | 0.120 |
Why?
|
SOXB1 Transcription Factors | 1 | 2016 | 286 | 0.120 |
Why?
|
Culture Media | 1 | 2016 | 899 | 0.110 |
Why?
|
Outpatients | 1 | 2021 | 1606 | 0.110 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2016 | 503 | 0.110 |
Why?
|
Medical Oncology | 1 | 2024 | 2321 | 0.100 |
Why?
|
Recovery of Function | 2 | 2020 | 2982 | 0.100 |
Why?
|
Risk Factors | 4 | 2024 | 74269 | 0.100 |
Why?
|
Income | 1 | 2020 | 1876 | 0.100 |
Why?
|
Risk Assessment | 2 | 2024 | 24086 | 0.090 |
Why?
|
Glucose | 1 | 2022 | 4361 | 0.090 |
Why?
|
Animals, Newborn | 1 | 2016 | 2671 | 0.090 |
Why?
|
Residence Characteristics | 1 | 2020 | 2058 | 0.090 |
Why?
|
RNA Interference | 2 | 2016 | 2846 | 0.090 |
Why?
|
Male | 12 | 2024 | 359413 | 0.090 |
Why?
|
Kidney | 1 | 2024 | 7072 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2024 | 64947 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4573 | 0.080 |
Why?
|
Female | 11 | 2024 | 391011 | 0.080 |
Why?
|
Insurance Coverage | 1 | 2020 | 1939 | 0.080 |
Why?
|
Antioxidants | 1 | 2016 | 1668 | 0.080 |
Why?
|
Cell Differentiation | 2 | 2016 | 11480 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2021 | 2544 | 0.070 |
Why?
|
Massachusetts | 1 | 2020 | 8805 | 0.070 |
Why?
|
Hospitals | 1 | 2020 | 3929 | 0.070 |
Why?
|
Sex Factors | 1 | 2020 | 10530 | 0.070 |
Why?
|
Hospitalization | 2 | 2023 | 10761 | 0.060 |
Why?
|
Databases, Factual | 1 | 2020 | 8018 | 0.060 |
Why?
|
Mesenchymal Stem Cells | 1 | 2014 | 1634 | 0.060 |
Why?
|
Benzylamines | 1 | 2024 | 248 | 0.050 |
Why?
|
Prognosis | 1 | 2024 | 29636 | 0.050 |
Why?
|
Age Factors | 1 | 2020 | 18415 | 0.050 |
Why?
|
Gene Expression | 1 | 2016 | 7592 | 0.050 |
Why?
|
Uracil | 1 | 2024 | 207 | 0.050 |
Why?
|
Obesity | 1 | 2024 | 12915 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2024 | 58947 | 0.050 |
Why?
|
Neprilysin | 1 | 2024 | 472 | 0.050 |
Why?
|
Aged | 6 | 2024 | 168995 | 0.050 |
Why?
|
Insulin | 1 | 2016 | 6592 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2014 | 4938 | 0.050 |
Why?
|
Middle Aged | 7 | 2024 | 220175 | 0.050 |
Why?
|
United States | 2 | 2020 | 72363 | 0.050 |
Why?
|
Time Factors | 2 | 2020 | 40133 | 0.040 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 2020 | 60 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2024 | 12412 | 0.040 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2024 | 329 | 0.040 |
Why?
|
Medicare | 1 | 2018 | 6771 | 0.040 |
Why?
|
Microvessels | 1 | 2024 | 572 | 0.040 |
Why?
|
Microcirculation | 1 | 2024 | 1279 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2014 | 10434 | 0.040 |
Why?
|
Chloroquine | 1 | 2020 | 277 | 0.040 |
Why?
|
Tetrazoles | 1 | 2024 | 901 | 0.040 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2020 | 124 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 283 | 0.040 |
Why?
|
Adult | 3 | 2024 | 219847 | 0.040 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 22025 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 607 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2021 | 80301 | 0.040 |
Why?
|
Postpartum Period | 1 | 2024 | 1168 | 0.040 |
Why?
|
Ventricular Remodeling | 1 | 2024 | 1259 | 0.030 |
Why?
|
Plasma | 1 | 2020 | 584 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 494 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 428 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22066 | 0.030 |
Why?
|
Syndrome | 1 | 2021 | 3278 | 0.030 |
Why?
|
Emergencies | 1 | 2021 | 1217 | 0.030 |
Why?
|
Aorta | 1 | 2021 | 2042 | 0.030 |
Why?
|
Young Adult | 1 | 2020 | 58673 | 0.030 |
Why?
|
Antimalarials | 1 | 2020 | 907 | 0.030 |
Why?
|
Anti-Bacterial Agents | 2 | 2021 | 7400 | 0.030 |
Why?
|
Coronary Vessels | 1 | 2024 | 3112 | 0.030 |
Why?
|
Adolescent | 1 | 2020 | 87747 | 0.020 |
Why?
|
Patient Care Team | 1 | 2023 | 2510 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2024 | 2296 | 0.020 |
Why?
|
Isoenzymes | 1 | 2014 | 1690 | 0.020 |
Why?
|
Protein Kinase C | 1 | 2014 | 1201 | 0.020 |
Why?
|
Myocardial Contraction | 1 | 2014 | 1516 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8487 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6457 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3061 | 0.020 |
Why?
|
Animals | 2 | 2016 | 167940 | 0.020 |
Why?
|
Transfection | 1 | 2014 | 5782 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2024 | 15827 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2449 | 0.020 |
Why?
|
Regeneration | 1 | 2014 | 1506 | 0.020 |
Why?
|
Pregnancy | 1 | 2024 | 29725 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 13300 | 0.010 |
Why?
|
Prospective Studies | 1 | 2024 | 54263 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2014 | 14396 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 18968 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41317 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18134 | 0.010 |
Why?
|
Signal Transduction | 1 | 2014 | 23363 | 0.010 |
Why?
|
Concepts
(141)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(52)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_